Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650775 | 0.88 | HDAC1 (0.44) | HDAC1GPR119HDAC2 | |
| SCHEMBL2685210 | 0.86 | GPR119 (0.43) | HDAC1GPR119HDAC2HPGDS | |
| SCHEMBL2134036 | 0.84 | CA2 (0.46) | HDAC1GPR119HDAC2 | |
| SCHEMBL4669170 | 0.84 | HDAC1 (0.48) | HDAC1HPGDS | |
| SCHEMBL4618383 | 0.83 | GPR119 (0.40) | HDAC1GPR119HDAC2HPGDS | |
| SCHEMBL1067203 | 0.81 | ABL1 (0.50) | HDAC1HDAC2 | |
| SCHEMBL449992 | 0.79 | DRD4 (0.36) | HDAC1GPR119HDAC2 | |
| SCHEMBL449808 | 0.77 | DHPS (0.42) | HDAC1GPR119HDAC2 | |
| SCHEMBL2137854 | 0.75 | GSK3B (0.43) | HDAC1HDAC2 | |
| SCHEMBL4579392 | 0.75 | HPGDS (0.46) | HDAC1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090062297-A1 | Hydroxyalkylarylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-1973405-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007087130-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC6 | HDAC1 1/4885GPR119 1448/4885HDAC2 4/4885 |
| US-20090062297-A1 | Hydroxyalkylarylamide Derivatives | AADAC, HDAC5, HDAC3 | HDAC1 6/4885GPR119 1522/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.